VEGFA and neoplasm: In addition to SoC, two therapeutics have received approval from the Food and Drug Administration, including (1) an anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab, and (2) tumor-treating fields that target proliferating tumor cells.